805250-21-9

Usage

Uses

Used in Organic Chemistry:
[1,1-Biphenyl]-3-methanol,2,4,6-trimethyl-(9CI) is used as a building block for the synthesis of more complex organic molecules. Its unique structure allows for various chemical reactions, making it a valuable component in the development of new compounds with specific properties and applications.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, [1,1-Biphenyl]-3-methanol,2,4,6-trimethyl-(9CI) may be utilized as an intermediate in the production of drugs with potential therapeutic effects. Its specific chemical properties could be exploited to design and develop novel pharmaceutical agents targeting various medical conditions.
Used in Material Science:
[1,1-Biphenyl]-3-methanol,2,4,6-trimethyl-(9CI) may also find applications in the field of material science, where its unique structural features could be employed to create new materials with specific properties. These materials could be used in various applications, such as in the development of advanced coatings, adhesives, or polymers with improved performance characteristics.

Upstream product

• 5980-97-2 mesitylboronic acid 
• 3132-99-8 m-bromobenzoic aldehyde 
• 805250-20-8 2',4',6'-trimethylbiphenyl-3-carbaldehyde 

Downstream Products

• 805248-76-4 methyl 2-{6-[(2',4',6'-trimethylbiphenyl-3-yl)methoxy]-2,3-dihydro-1-benzofuran-3-yl}acetate 
• 805248-77-5 {6-[(2',4',6'-trimethylbiphenyl-3-yl)methoxy]-2,3-dihydro-1-benzofuran-3-yl}acetic acid 

Relevant academic research and scientific papers

Identification of fused-ring alkanoic acids with improved pharmacokinetic profiles that Act as G protein-coupled receptor 40/free fatty acid receptor 1 agonists

The G protein-coupled receptor 40 (GPR40)/free fatty acid receptor 1 (FFA1) has emerged as an attractive target for a novel insulin secretagogue with glucose dependency. We previously identified phenylpropanoic acid derivative 1 (3-{4-[(2′,6′-dimethylbiphenyl-3-yl)methoxy]-2-fluorophenyl} propanoic acid) as a potent and orally available GPR40/FFA1 agonist; however, 1 exhibited high clearance and low oral bioavailability, which was likely due to its susceptibility to β-oxidation at the phenylpropanoic acid moiety. To identify long-acting compounds, we attempted to block the metabolically labile sites at the phenylpropanoic acid moiety by introducing a fused-ring structure. Various fused-ring alkanoic acids with potent GPR40/FFA1 activities and good PK profiles were produced. Further optimizations of the lipophilic portion and the acidic moiety led to the discovery of dihydrobenzofuran derivative 53 ((6-{[4′-(2-ethoxyethoxy)-2′,6′-dimethylbiphenyl-3-yl]methoxy} -2,3-dihydro-1-benzofuran-3-yl)acetic acid), which acted as a GPR40/FFA1 agonist with in vivo efficacy during an oral glucose tolerance test (OGTT) in rats with impaired glucose tolerance.

3-(4-BENZYLOXYPHENYL)PROPANOIC ACID DERIVATIVES

The present invention provides a novel compound represented by the formula (I) wherein each symbol is as defined in the specification, a salt thereof and a prodrug thereof having a superior GPR40 receptor function modulating action, which can be used as an insulin secretagogue, an agent for the prophylaxis or treatment of diabetes and the like. They unexpectedly show superior GPR40 receptor agonist activity, and also show superior properties as a pharmaceutical product, such as stability and the like. Thus, they can be safe and useful pharmaceutical agents for the prophylaxis or treatment of GPR40 receptor related diseases in mammals.